Institut Régional de Médecine Physique et de Réadaptation (IRR), Centre Louis Pierquin.
Nancy, 54000, France
Location status: Recruiting
NCT Number: NCT07349173
This study aims to evaluate the representation of action peripersonal space (PPS) in subjects suffering from unilateral segmental exclusion syndrome of the upper limb compared to healthy control subjects. Segmental exclusion is defined by non-use or under-use of a limb segment without central nervous system damage. The study hypothesizes that this syndrome leads to a modification (shrinkage) of the PPS representation. Participants will perform reachability judgments in a Virtual Reality (VR) environment.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Nancy, 54000, France
Location status: Recruiting
Segmental exclusion syndrome often occurs after limb trauma and manifests as a neglect-like behavior of peripheral origin, sometimes associated with Complex Regional Pain Syndrome (CRPS). The study explores whether the lack of limb use affects the representation of peripersonal space (PPS)-the space immediately surrounding the body where interactions with objects occur.
The study is monocentric, observational, with a matched control group. Participants will undergo:
Clinical assessment (questionnaires on pain, anxiety, body perception, and kinesiophobia).
A Virtual Reality (VR) test (approx. 40 minutes). In VR, participants will judge whether a cylinder presented at different distances and angles is reachable without moving (Perceived Reachable Distance - DMA-p). This will be compared to their Real Reachable Distance (DMA-r).
The goal is to measure the error of judgment to assess PPS representation and check for correlations with body schema disturbances or functional impairment
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(patients):
Inclusion criteria
(Controls):
Exclusion criteria
(All):
Participants wear an Oculus Quest 2 VR headset. They first perform a motor task to measure Real Reachable Distance (DMA-r). Then, they perform a perceptual task where they must judge, without moving, if a virtual object is reachable (DMA-p). The test evaluates different spatial planes (front, 45° right, 45° left) and heights (shoulder, navel).
Time frame: Day 1 (During the 40-minute VR assessment)
The Judgment Error of Reachability is a single composite metric calculated as: ((DMA-p - DMA-r) / DMA-r) × 100, expressed as a percentage (%).
Both DMA-p (Perceived Maximum Reachable Distance) and DMA-r (Real Maximum Reachable Distance) are measured in centimeters, and their ratio yields a single dimensionless percentage score.
Time frame: Day 1 (Before VR task)
Assessed using the Bath CRPS Body Perception Disturbance Scale (French version). Scores range from 0 to 57, with higher scores indicating greater disturbance.
Time frame: Day 1
Evaluated using the 400-Point Hand Assessment, which measures functional hand use. The score ranges from 0 to 400, where higher scores indicate better functional performance (better outcome).
Time frame: Day 1
Hospital Anxiety and Depression Scale. Scores range from 0 to 21 for each dimension (Anxiety and Depression).
Time frame: Day 1
Tampa Scale for Kinesiophobia (TSK). Assesses fear of movement. Scores range to 68; >40 indicates significant kinesiophobia.
Time frame: Day 1
Pain Catastrophizing Scale. Scores range from 0 to 52.
Contact information is provided by the study sponsor or research team.
Amélie Touillet, MD
CONTACT
Jonahtan Pierret, PhD
CONTACT
Union de Gestion des Etablissements des Caisses d'Assurance Maladie - Nord Est
Other
Study of the Representation of Action Peripersonal Space in Participants With Unilateral Segmental Exclusion of the Upper Limb Compared to Asymptomatic Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07361692
Anxiety Disorders, Autonomic Nervous System Diseases
Saint-Nazaire, France
View Trial DetailsNCT07610889
Autonomic Nervous System Diseases, Complex Regional Pain Syndrome (CRPS)
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT07093424
Autonomic Nervous System Diseases, Complex Regional Pain Syndrome (CRPS)
Şişli, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06987747
Autonomic Nervous System Diseases, Complex Regional Pain Syndrome (CRPS)
Hamilton, Ontario, Canada
View Trial Details